Curaleaf (OTCMKTS:CURLF) Shares Gap Up - Time to Buy?

Key Points

• Curaleaf shares gapped up Friday, opening at $2.29 versus Thursday's close of $2.2140 and last trading at $2.2525 on a volume of 58,693 shares.
• Analysts have been upgrading the stock—two Strong Buy, one Buy and one Hold—giving an average rating of Buy after recent raises from ATB Cormark and a reaffirmation from Alliance Global Partners.
• The company reported quarterly EPS of ($0.05), beating consensus (—$0.08) and revenue of $333.1M versus $328.7M, but it remains unprofitable with an 18.08% net margin and analysts forecast a full-year EPS of —$0.25.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $2.2140, but opened at $2.29. Curaleaf shares last traded at $2.2525, with a volume of 58,693 shares trading hands.

Analyst Ratings Changes

Several research firms have commented on CURLF. Alliance Global Partners reaffirmed a "buy" rating on shares of Curaleaf in a research report on Monday, December 22nd. ATB Cormark Capital Markets raised shares of Curaleaf to an "outperform" rating in a research report on Tuesday, December 2nd. Finally, Zacks Research upgraded Curaleaf from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Curaleaf currently has an average rating of "Buy".

Curaleaf Stock Performance

The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.71 and a current ratio of 1.52. The firm's 50 day moving average is $2.46 and its 200-day moving average is $2.68. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -7.62 and a beta of 0.71.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The firm had revenue of $333.07 million during the quarter, compared to the consensus estimate of $328.70 million. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. Analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company's vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf's product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.